PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1544544
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1544544
Anti-Obesity Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
Anti-Obesity Drugs Market size is projected to expand at a 27% CAGR from 2024 to 2032, led by increasing launches and innovations in drug development.
New anti-obesity medications are being introduced to offer improved efficacy and safety profiles for managing weight. Ongoing research and advancements in understanding the biological mechanisms of obesity are driving the development of more targeted and effective anti-obesity drugs. Furthermore, innovations in genomics and biotechnology are facilitating the creation of precise therapies tailored to the diverse needs of individuals grappling with obesity. For instance, in January 2024, Eli Lilly, the maker of the anti-obesity drug Zepbound, launched LillyDirect, a direct-to-patient portal. This initiative aimed to enhance access to anti-obesity medications while simplifying the treatment process and boosting patient engagement.
The overall market is segregated into product, action pathway, distribution channel, and region.
Based on product, the anti-obesity drugs market value from the OTC drugs segment is estimated to rise at a significant CAGR from 2024 to 2032, attributed to the growing demand for weight management solutions. OTC (over-the-counter) options are granting individuals easier access to combat obesity without needing a prescription. These OTC anti-obesity drugs also boast effective ingredients and safer profiles, bolstering weight loss endeavors.
The e-commerce distribution channel segment in the anti-obesity drugs market is set to experience substantial growth until 2032. This is driven by the increasing demand for accessible treatments. Consumers are turning to e-commerce platforms for their anti-obesity medications, drawn by convenience and wider selection. Online retailers are also diversifying their offerings, presenting various formulations and brands to cater to those pursuing weight management solutions.
Asia Pacific anti-obesity drugs market is poised for notable growth by 2032, largely due to escalating healthcare expenditures. Heightened investments in healthcare are channeling more resources into the development and distribution of anti-obesity treatments. Consequently, as healthcare expenditures continue to rise, they will bolster the expansion and accessibility of anti-obesity drugs. This that ensures a broader segment of the population can access effective solutions for obesity management, ultimately enhancing overall health in the region.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of obesity-related conditions
- 3.2.1.2 Government regulations and guidelines
- 3.2.1.3 Increase in technological advancements
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Side effects and adverse reactions
- 3.2.2.2 High cost of anti-obesity drugs
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Prescription drugs
- 5.3 OTC drugs
Chapter 6 Market Estimates and Forecast, By Action Pathway, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Peripherally acting drugs
- 6.3 Centrally acting drugs
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacies
- 7.3 Retail pharmacies
- 7.4 Drug stores
- 7.5 E-commerce
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Arena Pharmaceuticals, Inc.
- 9.2 AstraZeneca PLC
- 9.3 Boehringer Ingelheim International GmbH
- 9.4 Currax Pharmaceuticals LLC
- 9.5 Eli Lily and Co
- 9.6 F. Hoffmann-La Roche Ltd.
- 9.7 Gelesis
- 9.8 GlaxoSmithKline plc
- 9.9 Merck and Co., Inc.
- 9.10 Novartis AG
- 9.11 Novo Nordisk A/S
- 9.12 Orexigen Therapeutics, Inc.
- 9.13 Pfizer Inc.
- 9.14 Rhythm Pharmaceuticals, Inc.
- 9.15 Vivus, Inc.
